Alnylam and Medtronic are working together to develop RNA interference as a treatment for Huntington's disease, reports The Wall Street Journal. Medtronic is working the task of creating a pump and catheter system to deliver Alnylam's therapy to the right spot of the brain "without hiking up cranial pressure too much and damaging brain tissue," the Journal adds. Alnylam is using an siRNA to block mRNA. "What we do is shut off the spigot," Alnylam president Barry Greene says. "We stop the creation of a protein."
Premium Trial: